Your browser doesn't support javascript.
loading
Glucose-lowering effect of Reducose® enriched with 1-deoxynojirimycin and l-leucine: Studies on insulin secretion in INS-1 cells and reduction of blood glucose in diabetic rats.
Lee, Dahae; Baek, Ji Yun; Choi, Ye Jung; Han, Min Ji; Kim, Seon Hwa; Kim, Tae Hoon; Lee, Sanghyun; Kang, Ki Sung.
Afiliação
  • Lee D; College of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
  • Baek JY; College of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
  • Choi YJ; College of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
  • Han MJ; Vixxol Corporation, Gunpo, 15807, Republic of Korea.
  • Kim SH; Vixxol Corporation, Gunpo, 15807, Republic of Korea.
  • Kim TH; Vixxol Corporation, Gunpo, 15807, Republic of Korea.
  • Lee S; Department of Plant Science and Technology, Chung-Ang University, Anseong, 17546, Republic of Korea.
  • Kang KS; College of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Heliyon ; 10(3): e25499, 2024 Feb 15.
Article em En | MEDLINE | ID: mdl-38333854
ABSTRACT
The extract of mulberry leaf and its active ingredients have already been reported to have anti-diabetic effects; however, further studies are required to obtain better quality extracts and higher yields of active ingredients. Reducose® is a commercially available aqueous extract of mulberry leaves with a high content of active ingredients. In this study, the biological activities of Reducose®, 1-deoxynojirimycin, and l-leucine were evaluated using a glucose-stimulated insulin secretion (GSIS) assay. The GSIS assay results were expressed as the glucose-stimulated index (GSI). Considering the pharmacological safety in pancreatic ß-cells, the appropriate non-toxic concentrations were selected by screening for cytotoxicity of Reducose®, 1-deoxynojirimycin, and l-leucine before the GSIS assay. The effect of Reducose®, 1-deoxynojirimycin, and l-leucine on glucose-stimulated insulin secretion in INS-1 cells was compared. Reducose®, 1-deoxynojirimycin, and l-leucine increased the GSI values more effectively than gliclazide (positive control). This was associated with an increase in protein expression, such as peroxisome proliferator-activated receptor-γ, insulin receptor substrate-2, activated pancreatic and duodenal homeobox-1, which are related to the regulation of pancreatic ß-cell function and survival. In order to elucidate the effect of Reducose® in anti-diabetic effects, blood glucose levels, insulin levels, and liver and lipid concentrations were investigated in a Sprague-Dawley rat model of high-fat diet/streptozotocin-induced diabetes. We observed that administration of Reducose® can decrease fasting blood glucose levels and reduce the production of AST, ALT, TG, and TC to a similar extent as metformin (positive control). These results suggested that Reducose® play a role in promoting GSIS but not enough to show that the content and proportion of 1-deoxynojirimycin and l-leucine play an important role in the GSIS activity of Reducose®.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Heliyon Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Heliyon Ano de publicação: 2024 Tipo de documento: Article